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In the in vivo experiments on anaesthetized sheep, it was presently examined whether muscarinic receptor antagonists with
diverse selectivity aﬀect the release of VIP in response to electrical stimulation of the parasympathetic chorda tympanic nerve
diﬀerently, and if the changes in the release could be associated to altered secretory and vasodilator responses. The location of
the muscarinic receptor subtypes was examined also. In the experiments, blood was collected out of the submandibular venous
drainage before and during electrical stimulation of chorda tympani nerve in the absence and presence either of pirenzepine
or methoctramine. While metchoctramine increased the output of protein, pirenzepine inhibited ﬂow of saliva and increased
protein output, vasodilatation, and VIP output. In morphological examinations, the inhibitory muscarinic M4 receptor occurred
interacinarily in the gland. It is concluded that prejunctional muscarinic receptors, most likely of the M4 subtype, exert inhibitory
modulation of the parasympathetic release of VIP in the ovine submandibular gland.
Copyright © 2009 Anders T. Ryberg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The ﬂuid secretory response of the ovine submandibular
gland to acetylcholine is exerted via both muscarinic M1 and
M3 receptors, while M5 receptors also seem to participate
in the cholinergic vasodilator response [1]. However, in
the parasympathetic glandular neurons, the neuropeptide
vasoactive intestinal peptide (VIP) may be colocalised with
acetylcholine [2]. In the submandibular gland of the sheep,
VIP is present in nerve terminals adjacent to both small
blood vessels and acini [3]. In this gland as well as in the
ovine parotid gland, VIP mediates secretion of protein-rich
submandibular saliva, in addition, the vasodilator eﬀects [4–
6]. However, VIP is remarkably potent in eliciting protein
secretion from salivary glands in a number of species [7–11],
andVIPseemstoplayaroleinhumansubmandibularglands
also, both regarding secretion and vasodilatation [12–14].
At the postjunctional level, VIP and acetylcholine interact
and at simultaneous administration of the exogenous VIP
and a muscarinic agonist, conspicuous positive synergies
emerge [7, 8, 15]. The crosstalk between the two transmitter
substances occurs at prejunctional level also [6, 16, 17]. In
the ovine submandibular gland, intravenous injections of
the “M2/4”-selective antagonist methoctramine signiﬁcantly
increased the parasympathetic nerve-evoked secretion of
protein [1]. Also, unselective muscarinic receptor blockade
of prejunctional receptors has been shown in a number
of species to increase VIPergic responses together with the
release of VIP upon electrical stimulation of the parasym-
pathetic glandular innervation [6, 18, 19]. The eﬀect of the
blockade of the prejunctional receptors seems to be unspe-
ciﬁc and aﬀects both the release of the neuropeptide VIP and
the classical parasympathetic transmitter acetylcholine [17].
In contrast to acetylcholine, VIP is preferentially released
during intense parasympathetic stimulation [20]. Therefore
it was presently wondered whether or not blockade with
muscarinic receptor antagonists with diﬀerent selectivity
proﬁle aﬀects the release of VIP in response to electrical2 Advances in Pharmacological Sciences
stimulation of the parasympathetic chorda tympanic nerve
diﬀerently, and, if so, the changes in the release could
be associated to alterations in secretory and vasodilator
responses. For this purpose blood was collected out of the
submandibular venous drainage before and during electrical
stimulation of the ovine chorda tympani nerve at a high
frequency (8Hz) in the absence and presence either of the
muscarinic “M1-selective” receptor antagonist pirenzepine
or the muscarinic “M2/4-selective” receptor antagonist
methoctramine [21]. In order to look for morphological
correlates to the functional ﬁndings, the expression and
cellular location of the diﬀerent muscarinic receptors were
assessed by immunohistochemistry.
2. Methods
2.1. Animals. The experiments were carried out on 11 adult
ewes of various breeds (35–72kg body weight) under the
Animals Scientiﬁc Procedures Act (1986); Project Licence
PPL 80/1316. The in vivo experiments were performed at
the Physiological Laboratory, Cambridge University, and the
ethics Committee of the Cambridge University approved
the study design. Food but not water was withheld for 48
hour prior to each experiment. Anaesthesia was induced and
maintained with sodium pentobarbitone (Sagatal, Rhˆ one
M´ erieux Ltd., Harlow, UK; 15–30mgkg−1 IV (via a catheter
in the femoral vein) and then 0.1–0.3mgmin−1 kg−1 IV
(adjusted to maintain a stable blood pressure)). Surgery
was performed as been described previously [1]. In short,
the trachea was intubated, and the ipsilateral ascending
cervical sympathetic nerve was cut. Via a catheter in the
femoral artery, the arterial blood pressure was monitored.
The chorda-lingual nerve was exposed and cut, and the
submandibular duct was cannulated. No spontaneous ﬂow
of saliva occurred. Each of the tributaries of the ipsilateral
linguofacial vein, except that draining the submandibular
gland, was ligated. The animal was heparinized (Mutiparin,
CP Pharmaceuticals, Wrexham, UK; 1000IUkg−1 IV), the
linguofacial vein cannulated, and the submandibular venous
eﬄuent diverted through a photoelectric drop counter and
returnedtotheanimalbyapump.Finally,abipolarplatinum
stimulating electrode was placed under the duct and the
chorda tympani close to the hilum of the gland. The protocol
involved parasympathetic stimulation at 8Hz continuously
for 10minutes (20-V square wave; 10-ms pulse width). At
the end of each experiment the animal was given a lethal
dose of barbiturate (Pentoject, Animalcare Ltd., York, UK;
ca 15mL 20% w/v), and the contra-lateral submandibular
gland dissected out and weighed (12 ± 1g; n = 11).
Regarding the samples of blood, these were weighed for
gravimetric estimation of blood ﬂow and then returned to
the animal to preserve the circulating blood volume, except
for that volume of submandibular venous eﬄuent blood
kept for VIP estimations. The gravimetrical measurement
ensured a high degree of accuracy since the blood ﬂow
occasionally increased so much that the drop counter did
not discriminate between the single drops; all blood ﬂow
data presented are calculated from the gravimetrical mea-
surements. Arterial blood samples were collected from the
femoral artery at intervals for calculations of the glandular
release of VIP into the circulation; the diﬀerence between
arterial and venous VIP concentration, which is the actual
data presented in the result section. The samples were
collected into chilled preweighed tubes containing aprotinin
(2500KIUmL blood−1) and then centrifuged at +4◦Ca s
soon as possible and the plasma sequestered at −20◦C.
Plasma VIP concentrations were measured by an enzyme
immunoassay (EIA for VIP, Peninsula Laboratories Inc.,
Calif, USA). The minimum detectable concentration for VIP
was 0.02pmolmL−1 (range 0–7.6pmolmL−1; linear range
0.03–0.61pmolmL−1). The saliva samples were analyzed for
its protein content by the Lowry method [22]. Regarding the
protein secretion, this is given as the protein output and thus
disregarding the salivary ﬂow rate; that is, it is not given as
protein concentration.
2.2. Immunohistochemistry. After administration of a lethal
doseofanesthetic,tissuefromthecontralateralsubmandibu-
lar gland was dissected out from the animal for histological
examinations. A part (central, lower part) of glandular
tissue of the parts most proximal to the glandular hilus was
removed. The specimens were ﬁxed in phosphate buﬀered
4% paraformaldehyde (pH 7.0), and then embedded in
paraﬃn.
For the immunohistochemical investigation of mus-
carinic receptor expression, transverse sections of the dif-
ferent specimens were prepared in a cryostat at a thickness
of 4μm .T h es e c t i o n sw e r ed e p a r a ﬃnized by heating the
slides to 60◦C for 15 minutes and then subjected to two
30-minute changes in 100% xylene; the sections were then
rehydrated by serial incubations in 100%, 95%, 85%, and
70% ethanol, followed by tris-buﬀered saline (TBS). Then
the sections were immersed in 10mM citrate buﬀer (pH
6.0) and were microwaved for four cycles of 4 minutes.
Endogenous peroxidase was blocked with 0.03% hydrogen
peroxidase for 30 minutes. Nonspeciﬁc protein binding was
blocked with 5% bovine serum albumin (BSA) in TBS for 30
minutes. The sections were thereupon incubated overnight
at 4◦C in a humidiﬁed chamber with polyclonal rabbit anti-
mAChR subtype speciﬁc antibodies (Research and Diagnos-
tic Antibodies, Berkley,USA) diluted 100x in TBS containing
1% BSA. The presence of the muscarinic receptors was
revealed using an avidin-biotin-complex immunoperoxidase
method (ABC Staining System, Santa Cruz Biotechnology,
Santa Cruz, USA; system used following the manufacturer’s
instructions) that uses 3,3P-diaminobenzidine (DAB) as a
substrate. The sections were counterstained using Mayer’s
hematoxylin. As a negative control, duplicate sections
were immunostained without exposure to the primary
antibody, which resulted in no brown staining of the
tissue.
2.3. Estimations. Submandibular vascular resistance (SVR)
wasestimatedbydividingtheperfusion(arterialblood)pres-
sure (mmHg) by the submandibular blood ﬂow (μlmin −1
[g gland]−1) and expressed as the % changes. Results are
expressed as mean values ± S.E.M. and were assessed
statistically by means of two-way ANOVA followed byAdvances in Pharmacological Sciences 3
posttest of Bonferroni. All ﬂows and outputs are expressed
per unit weight of the contralateral gland.
3. Results
3.1. Vasodilator and Secretory Responses to Stimulation of
the Parasympathetic Innervation. In the absence of stimu-
lation, the submandibular gland was quiescent according
to secretion, while the mean basal glandular blood ﬂow
was 0.26 ± 0.04mLmin−1ggland −1 in the group (n = 6)
in which the eﬀect of pirenzepine was examined. In the
group examining the eﬀect of methoctramine the basal
blood ﬂow was 0.32 ± 0.05mLmin−1ggland −1 (n = 5).
Also, the blood pressure was almost identical in the two
groups (93 ± 5v s9 1± 4mmHg), and neither antagonist
aﬀected the pressure. Electrical stimulation of the chorda
tympani at 8Hz evoked a mean ﬂow of saliva over the 10-
minutesstimulationatof78±3and59±4μlmin −1 ggland −1
before administration of pirenzepine and methoctramine,
respectively. Correspondingly, the mean decreases in sub-
mandibular vascular resistance in the absence of antagonist
were −78 ± 0.5a n d−72 ±0.5%, respectively. These changes
in vascular resistance reﬂected mean blood ﬂow during
the stimulation of 1.23 ± 0.06 (in absence of antagonist;
pirenzepine group) and 1.19 ± 0.05mLmin−1ggland −1 (in
absence of antagonist; methoctramine group). The mean
protein output over the stimulation period was in the two
groups 61 ±9a n d5 8±7μgmin −1 ggland −1,r e s p e c t i v e l y .
3.2. Responses Following the Administration of Muscarinic
Antagonists. The intravenous administration of methoc-
tramine100μgkg −1 (n = 5)hadnoeﬀectneitherontheﬂow
of saliva (Figure 1(a)), the vascular resistance (Figure 1(c)),
or on the submandibular output of VIP (Figure 1(d)).
The overall output of protein increased in the presence
of methoctramine (+110 ± 36%; P<. 001), although
no signiﬁcance was attained for the separate points in
time (Figure 1(b)). Pirenzepine (40μgkg −1 IV; n = 6)
signiﬁcantly reduced the ﬂow of saliva by about 30%.
The overall vasodilator (+10 ± 5%; P<. 01) as well as
the protein secretory responses (+119 ± 30%; P<. 001)
both increased signiﬁcantly. Both responses also attained a
signiﬁcant increase during the second half of the stimulation
period.
3.3. VIP Release. The concentration of VIP in the sub-
mandibular venous eﬄuent plasma during chorda tympani
stimulation at 8Hz rose steadily during the stimulation
period. The basal release of VIP in the absence of stimulation
amounted to 0.09 ± 0.03pmolmL−1. When the chorda
tympani nerve was challenged by the electrical stimulation
in the absence of antagonist, the VIP output increased
by 9 to 11 times. After the intravenous administration of
methoctramine, the total mean VIP output over the 10-
minutes stimulation was not signiﬁcantly increased. In the
presence of pirenzepine, no changes in the VIP occurred
during the ﬁrst two periods of stimulation, whereas it was
conspicuously increased in the third period of stimulation
(increased 16 times; P<. 01; Figure 1(d)).
3.4. Immunohistochemistry. In the immunohistochemical
examination, all muscarinic receptor subtypes except the M2
receptor were detected in the submandibular acinar tissue
(Figure 2). In the glandular stroma, clear staining for the
muscarinic M4 receptor appeared. Occaisonally, a vague
staining for the muscarinic M1 receptor seems to occur also,
but no staining was detected interacinarily for the other
subtypes.
4. Discussion
By studying the functional responses to the stimulations,
correlates to the variations in the VIP output were searched
for. By immunohistochemistry examination, morphological
correlates were also looked for. The functional parameters,
that is, ﬂuid and protein secretion and vasodilator responses,
were almost identical to those reported previously [1]. In
the current report, observations were only performed at a
high frequency of stimulation (8Hz). Neuropeptides, such
as VIP, are preferentially released at intense stimulation of
the nerve. Previously, activation of prejunctional muscarinic
receptors has been shown to inhibit the release of VIP in
salivary glands of cats, ferrets, sheep, and rats [6, 18–20],
and the eﬀect on the neuronal release has been shown to
have impact on secretion as well as on vasodilatation [16,
20]. In other organs, the pharmacological characterization
of muscarinic prejunctional inhibitory receptors suggests
the receptors to be of either the M2 or the M4 subtype
[17, 23–27]. However, morphological observations made
in salivary glands indicate that prejunctional muscarinic
receptors could be of the M1, M4, and the M5 receptor
subtypes [28, 29]. In experiments on knockout mice, the
inhibitory muscarinic receptors located prejunctionally have
been shown to be of the M4 subtype and not muscarinic M2
receptors [30].
In the current experiments, pirenzepine reduced the
nerve stimulation-induced increases in salivary ﬂow. Even
though there exists VIP-evoked as well as an atropine-
resistant parasympathetic ﬂuid response; muscarinic recep-
tor stimulation is the principal stimulus for ﬂuid secretion
in the actual gland [1, 6]. In view of the small VIPergic
response, the pirenzepine inhibition of the ﬂow of saliva
evoked by parasympathetic nerve stimulation is likely to
be an eﬀect on glandular muscarinic receptors, which is in
accordance with our previous report showing the occurrence
of muscarinic M1 receptors on acinar cells [1]. However, all
other parameters, that is, protein output, vasodilatation, and
VIP release, were increased after pirenzepine administration.
Although pirenzepine preferentially binds to muscarinic M1
receptors, the selectivity window of muscarinic antagonists
is very narrow and to say that the antagonists are selective
for a speciﬁc subtype is erroneous, even for pirenzepine.
Pirenzepine shows about 100 times greater aﬃnity for M1
than for M2 receptors, but it shows only about 5 times
greater aﬃnity for the M1 over the M4 receptor [21]. An
eﬀect by pirenzepine on acinar excitatory receptors (e.g.,
M1 receptors) would of course result in a reduction of
the ﬂuid response as presently was observed. If this had











































































































































































































































































Figure 1: Comparison of the changes in submandibular ﬂow of saliva (A), submandibular protein output (B), submandibular vascular
resistance (C), and VIP output (D) in response to chorda tympani stimulation at 8Hz continuously for 10 minutes (from point of time 0
to 10; indicated by horizontal bar) in the absence () and in the presence () of methoctramine (left column of panels; 100 μgkg −1 IV) in
5 anesthetized sheep and in the absence () and in the presence () of pirenzepine (right column of panels; 40μg/kg iv) in 6 anesthetized
sheep. Values are means ± S.E.M.Advances in Pharmacological Sciences 5
(a) (b) (c)
(d) (e) (f)
Figure 2: Immunohistochemical labelling of submandibular
glands. Images demonstrate staining in absence of antibody (a;
control); staining in the presence of muscarinic M1 (b), M2 (c), M3
(d), M4 (e), and M5 (f) receptor antibodies. Bar in panels indicates
10μm.
been diminished. However, since it increased in spite of the
reduction of the ﬂuid response, the reason must be found in
increased stimulation of protein secretion, for instance, by
a potent protein secretagogue such as the cotransmitter VIP
[4]. An antagonistic eﬀect resulting in increased responses
is produced by blockade of inhibitory receptors (muscarinic
M2orM4receptors).Concerningtheaﬃnityofthecurrently
used antagonists on these receptors, it is close to identical
on M4 receptors, whereas methoctramine has 30 times
greater aﬃnity on M2 receptors than pirenzepine. While
pirenzepine signiﬁcantly increased the protein output, the
vasodilatationandthereleaseofVIP,methoctramineshowed
tendencies towards the same pattern. Therefore, an eﬀect via
M 4r e c e p t o r si sm o r el i k e l yt h a na ne ﬀect on muscarinic M2
receptors.
A striking phenomenon within the current results is that
the release of VIP and the VIP archetypical responses, that
is, protein secretion and vasodilatation, went in parallel.
The fact that the blockade caused increases in the responses
favours the idea that the eﬀects are caused by blockade
of inhibitory receptors. In the morphological examination,
muscarinic receptors seem to occur in stromal parts of the
glandular tissue, which is in accordance to where nerve
ﬁ b r e sh i s t o l o g i c a l l yh a v eb e e nd e s c r i b e d[ 31]. In the current
morphological examination, staining for the muscarinic
M4 receptor and possibly also for the muscarinic M1
receptor was detected. Since no muscarinic M2 receptors
have been detected in the morphological examinations,
neither currently nor in previous observations on the
ovine submandibular gland [1], it seems reasonable to
conclude that inhibitory muscarinic receptors of the M4
subtype are localized prejunctionally. Since prejunctional
facilitator receptors of the M1 subtype have been described
in other salivary glands [17]; such receptors could possibly
occur in the ovine submandibular gland also. All in all,
the current observations show that inhibitory muscarinic
receptors modulate the neuronal release of transmitters in
the submandibular gland of the sheep and that these are
likely to be of the muscarinic M4 receptor subtype.
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